DailyIQ
Last updatedjust now

VEA·Vanguard FTSE Developed Markets ETF

$69.28
-0.78 (-1.11%)
High
$69.80
Open
$69.55
Net Assets
$313.5B
52W High
—
Low
$69.10
P. Close
$69.28
Expense Ratio
0.03%
52W Low
—
Div. Yield
1.35%
Next Ex-Div
~Dec 18
Top 10 Weight
12.5%
Category
Foreign Large Blend
Inception
Jan 4, 2001
Technical Score (1D)
66
BULLISH
News Sentiment
57
BULLISH

What's happening to VEA today?

The VEA ETF was reported to have holdings in Roche (RHHBY) and Shell (SHEL) on October 14. On October 13, Roche announced a $100 million upfront payment to China‑based Rona Therapeutics for full ownership of an experimental RNA interference drug targeting ALK7, with the agreement potentially exceeding $1 billion if development, regulatory and commercial milestones are met. The same day Roche entered into an exclusive worldwide licensing agreement with Rona for the investigational ALK7‑targeting RNAi therapy for obesity and metabolic diseases, allowing Roche to develop and commercialise the candidate globally while Rona could earn up to $1.16 billion in milestone payments. On October 13, Shell plc raised its third‑quarter 2026 Integrated Gas production guidance while keeping LNG liquefaction, refinery utilisation and chemicals plant run‑rates on track, signalling stronger operational momentum in core hydrocarbons. The same day Shell shares closed at $102.99, up 1.38%, outperforming the S&P 500 and reflecting confidence in the company’s financial outlook ahead of the October 29 earnings release. Earlier in the week, analysts had projected a 74.73 % earnings‑per‑share jump to $3.25 and a 31.67 % revenue rise to $92.71 billion for the quarter, with year‑to‑date consensus estimates forecasting earnings of $11.51 per share and revenue of $379.46 billion. Shell also attracted attention for its dividend quality, achieving a 3.88 % yield that outperformed many peers while maintaining a conservative payout ratio that supports long‑term dividend sustainability.